| Essential Hypertension
Edarbi vs Azor
Side-by-side clinical, coverage, and cost comparison for essential hypertension.Deep comparison between: Edarbi vs Azor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAzor has a higher rate of injection site reactions vs Edarbi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Azor but not Edarbi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Edarbi
Azor
At A Glance
Oral
Once daily
Angiotensin II receptor blocker
Oral
Once daily
CCB / ARB combination
Indications
- Essential Hypertension
- Essential Hypertension
Dosing
Essential Hypertension 80 mg orally once daily; consider a starting dose of 40 mg for patients treated with high doses of diuretics. May be administered with or without food and with other antihypertensive agents.
Essential Hypertension Starting dose 5/20 mg once daily; may be increased after 1-2 weeks to a maximum of 10/40 mg once daily as needed to control blood pressure.
Contraindications
- Coadministration of aliskiren-containing products in patients with diabetes
- Co-administration of aliskiren in patients with diabetes
Adverse Reactions
Most common diarrhea, nausea, asthenia, fatigue, muscle spasm, dizziness, dizziness postural, cough
Postmarketing rash, pruritus, angioedema
Most common (>=3%) Edema
Postmarketing (amlodipine) Gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder
Postmarketing (olmesartan medoxomil) Asthenia, angioedema, anaphylactic reactions, peripheral edema, vomiting, diarrhea, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, alopecia, pruritus, urticaria
Pharmacology
Azilsartan is an angiotensin II receptor blocker (ARB) that selectively blocks binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland, inhibiting vasoconstriction and aldosterone secretion; azilsartan medoxomil is a prodrug rapidly converted to azilsartan by esterases during gastrointestinal absorption.
Azor combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium ion influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance, with olmesartan medoxomil, an angiotensin II receptor blocker that selectively blocks AT1 receptors in vascular smooth muscle to oppose the vasoconstrictor effects of angiotensin II.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Edarbi
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (7/12) · Qty limit (11/12)
Azor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Edarbi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Azor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Edarbi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Azor
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Edarbi.
No savings programs available for Azor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.